Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review

Amy Grove, Osemeke Osokogu, Lena Al-Khudairy, Amin Mehrabian, Mandana Zanganeh, Anna Brown, Rachel Court, Sian Taylor-Phillips, Olalekan A Uthman, Noel McCarthy, Sudhesh Kumar, Aileen Clarke

ABSTRACT

Objective To systemically review and critically appraise published studies of the association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19, including clinical course, morbidity and mortality outcomes.

Design Systematic review.

Data sources MEDLINE (OVID), Embase (OVID), Cochrane Central Register of Controlled Trials, MedRxiv and BioRxiv preprint databases. COVID-19 databases of the WHO, Cochrane, CEBM Oxford and Bern University up to 10 June 2020.

Study selection Studies that assessed vitamin D supplementation and/or low serum vitamin D in patients acutely ill with, or at risk of, severe betacoronavirus infection (SARS-CoV, MERS-CoV, SARS-CoV-2).

Data extraction Two authors independently extracted data using a predefined data extraction form and assessed risk of bias using the Downs and Black Quality Assessment Checklist.

Results Searches elicited 449 papers, 59 studies were eligible full-text assessment and 4 met the eligibility criteria of this review. The four studies were narratively synthesised and included (1) a cross-sectional study (n=167) suggesting an inverse association between serum vitamin D and SARS-CoV-2; (2) a retrospective cohort study (348 598 participants, 449 cases) in which univariable analysis showed that vitamin D protects against COVID-19; (3) an ecological country level study demonstrating a negative correlation between vitamin D and COVID-19 case numbers and mortality; and (4) a case–control survey (n=1486) showing cases with confirmed/probable COVID-19 reported lower vitamin D supplementation. All studies were at high/unclear risk of bias.

Conclusion There is no robust evidence of a negative association between vitamin D and COVID-19. No relevant randomised controlled trials were identified and there is no robust peer-reviewed published evidence of association between vitamin D levels and severity of symptoms or mortality due to COVID-19. Guideline producers should acknowledge that benefits of vitamin D supplementation in COVID-19 are as yet unproven despite increasing interest.

Strengths and limitations of this study

The strengths of this systematic review include that it is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.

The review was conducted by two independent reviewers to ensure robustness of this work.

We searched multiple living systematic review databases to enable us to capture publications in a fast-moving field of research.

The limitations of the study relate to the small amount of evidence available which was at risk of bias and which limits the inferences that can be drawn.

The review was restricted to the English language; therefore, non-English language papers may have been missed.

INTRODUCTION

COVID-19, a novel viral infection caused by SARS-CoV-2, was declared a pandemic by the WHO on 11 March 2020.1 Mild COVID-19 may manifest as high temperature, a continuous cough and a loss of or change in sense of smell or taste.2 3 However, more severe and critical cases can result in inflammation of the lungs, low oxygen levels and acute respiratory distress syndrome.4 Interest is mounting regarding the association of vitamin D supplementation or level with susceptibility to COVID-19 due to the recognised modulating...
effects of vitamin D on the immune system and immune response.

Vitamin D can modulate the immune system through highly expressed receptors in most non-skeletal tissues.\(^1\)\(^6\) Two of the most common analogues of vitamin D which are found in food and used as a dietary supplement are \(\text{D}_2\) (ergocalciferol) and \(\text{D}_3\) (cholecalciferol, also made by the skin when exposed to sunlight).\(^7\) Both \(\text{D}_2\) and \(\text{D}_3\) can be hydroxylated by liver enzymes CYP2R1 and CYP27A1 to form calcidiol (25(OH)D). The active metabolite of vitamin D, calcitriol (1\(,\)25(OH)2D), results from the action of CYP27B enzyme on calcidiol. CYP27B is found in several tissues including the kidney, skin, bones and immune system.\(^8\)\(^9\) Tumour necrosis factor-\(\alpha\) (TNF-\(\alpha\)) and interferon-\(\gamma\) (IFN-\(\gamma\)) are examples of inflammatory cytokines that stimulate the CYP27B enzymes of the immune system.\(^10\)\(^-\)\(^20\) Vitamin D can interact with both the innate and the cellular immune systems through these mechanisms.

Current Public Health England (PHE),\(^21\) National Institutes of Health\(^22\) and European Food Safety Authority\(^23\) recommendations highlight the importance of vitamin D to population health. Vitamin D deficiency is defined as less than 25 nmol/L (10 ng/mL) measured in blood serum.\(^21\) The UK guideline recommendations suggest that people take a supplement of 10 \(\mu\)g of vitamin D per day during the winter months or throughout the year if they do not spend time outdoors or if they cover the majority of their skin when outside.\(^21\) Published editorials, journal commentaries\(^24\)\(^-\)\(^29\) and news media reports\(^30\)\(^-\)\(^32\) suggest that individuals with low blood serum concentrations of vitamin D might be at higher risk of infection with COVID-19, or on infection have worse outcomes than individuals with normal/high serum vitamin D.\(^33\)

Several observational studies have reported associations between low serum vitamin D and chronic\(^31\) and acute conditions such as susceptibility to acute respiratory tract infections (RTI)\(^35\)\(^-\)\(^37\). Most recently, Martinac and colleagues conducted a systematic review and meta-analysis of individual participant data from randomised controlled trials (RCTs) to assess the overall effect of vitamin D supplementation on risk of acute RTI.\(^38\) They reported vitamin D supplementation to be safe while protecting against acute RTI overall (adjusted OR 0.88, 95% CI 0.81 to 0.96; \(p\) for heterogeneity <0.001). Patients very deficient in vitamin D benefited the most (adjusted OR 0.75, 0.60 to 0.95; \(p\) for interaction=0.006).\(^38\) Critiques of this review have suggested that the findings should be interpreted as hypothesis generating only, as the results are heterogeneous and not sufficiently applicable to the general population.\(^39\) Recent rapid reviews of vitamin D for treatment or prevention in COVID-19 reported no evidence to assess the association of vitamin D supplementation or level with susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes.

**METHODS**

**Protocol registration**

The methods were prespecified in a protocol that was registered with the PROSPERO International Prospective Register of Systematic Reviews (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020182876). Research ethics committee approval was not required for this study.

We undertook a systematic review to answer the following question: Is vitamin D supplementation or level associated with susceptibility to severe betacoronavirus infection (SARS-CoV, Middle East respiratory syndrome (MERS-CoV), SARS-CoV-2) including clinical course, morbidity and mortality outcomes?

Our review was conceptualised and written in accordance with the PRISMA statement.\(^43\)

**Data sources and search**

The search strategy was developed by the information specialists in collaboration with the research team and clinical advisors. We searched MEDLINE (OVID interface), Embase (OVID interface), Cochrane Central Register of Controlled Trials, MedRxiv and BioRxiv preprint databases on 6–8 May 2020. We searched the global research on COVID-19 developed by the WHO,\(^44\) CEBM Oxford\(^45\) and the living systematic review developed by Bern University\(^46\) on 10 May 2020. We updated the database searches on 10 June 2020 to capture articles which may have been published since the initial search was conducted.

We searched additional resources including relevant systematic reviews in MEDLINE (OVID interface), Embase (OVID interface) and Cochrane Database of Systematic Reviews, 19 May 2020), relevant references and contacted experts for additional evidence. Our full search record is included in the online supplemental file 1.

**Study eligibility**

We developed predefined study eligibility criteria aligned to the research question (box 1). We imposed a date restriction of January 2002 to capture all published articles since SARS-CoV was first discovered in Asia in February 2003.\(^47\) We limited to English language only.

**Article selection**

Following the article search, we systematically identified and removed any duplicate citations using EndNote V.X9 software. Using titles and abstracts, deduplicated citations were screened by two independent reviewers (OO, MZ, AM, AG) and checked by a third (AC). All articles deemed ineligible were excluded at this stage. We
identified and obtained all remaining articles for full-text screening, which was performed independently by at least two reviewers against the prespecified eligibility criteria (box 1). Where disagreements regarding the inclusion of articles arose, a third reviewer (AC) was consulted to reach a final decision.

Data extraction

Two reviewers independently (LA-K, MZ, OO, AM) extracted data from eligible full-text papers using a prespecified data extraction form. The accuracy of all the data extraction was independently assessed by a third reviewer (AG). Where reported, we sought to extract data from each article relevant to the research question, including details of population, intervention/exposure, comparator, outcomes and any detail related to the two prespecified subgroups: ethnicity characteristics and age characteristics. Disagreements between reviewers were resolved by discussion and agreement or via consultation with a third reviewer (AC).

Risk of bias

The included studies had observational study designs aimed at answering a specific question. Therefore, risk of bias of included full-text papers was assessed using the Downs and Black Quality Assessment Checklist.48 Two reviewers (AM, MZ, OO) independently assessed the risk of bias of the included studies and the accuracy of the assessment was evaluated by a third reviewer (LA-K).

Data analysis

We anticipated that identified studies would be too heterogeneous to facilitate pooling of study data and planned a narrative synthesis. Nevertheless, we intended to consider pooling outcomes data in a meta-analysis using a random-effects model if appropriate.

Patient and public involvement

Due to the rapid timeframe of this systematic review, it was not possible for our research team to involve patients or the public in the design, conduct or reporting of our study.

RESULTS

After searching databases, assessing the reference lists of 17 narrative reviews27 28 33 49–62 and one additional article identified through consultation with clinical experts,38 we identified 499 citations. Following removal of duplicates and screening of titles and abstracts, we retrieved 59 full-text papers, of which 4 met the full eligibility criteria (see figure 1). The electronic supplement includes a list of reasons for excluding studies at full-text review. Seven articles closely met the eligibility criteria but were excluded as they were not available as peer-reviewed publications at the time of our narrative synthesis, details of these seven studies63–69 is provided in the online supplemental material.

The characteristics of the four included studies are presented in table 1. All four included studies were conducted in Europe and published in April or May 2020. One study was based on data from UK residents exclusively,70 another included data on residents in 20 European countries, including the UK.71 The studies were observational design and no relevant RCT were identified or included in the review. All four studies were at high or unclear risk of bias and scored poorly across several domains of the Downs and Black Quality Assessment Checklist,46 including external validity, internal validity and power. A prominent issue among the included studies was that the authors did not perform adequate multivariable adjustment to correct for confounding.72–74 Ecological bias was present in Ilie et al,71 which may result from spatial and temporal scale differences between country level mean levels of vitamin D. However, several domains in each risk of bias assessment were not applicable or not reported and, therefore, could not be scored using the Downs and Black Quality Assessment Checklist.46 Detailed risk of bias scores are provided in the online supplemental material.

Serum vitamin D

D’Avolio et al73 used a cross-sectional design with data on nasopharyngeal swab PCR analysis for SARS-CoV-2 and a 25(OH)D measurement taken from patients between 1 March and 14 April 2020. PCR positives (median age=74 years (IQR 65–81); male=70.4%) had significantly (p=0.004) lower serum 25(OH)D levels (median=11.1
ng/mL (IQR 8.2–21.0)) than PCR negatives (median age=73 years (IQR 61–82); male=48.8%; median 25(OH) D=24.6 ng/mL (IQR 8.9–30.5)). Although gender-stratified and age-stratified analysis showed no significant differences, older (>70 years) SARS-CoV-2 positive (n=18) participants had significantly lower median serum 25(OH)D levels (9.3 ng/mL (IQR 8.1–19.9)) than older SARS-CoV-2 negatives (n=43) (23.1 ng/mL (IQR 8.5–31.7)) (p=0.037).

Hastie et al. used a retrospective cohort study that used data from the UK Biobank, using data from 348,598 people with complete information on vitamin D and covariates; 449 people tested positive for COVID-19. COVID-19 positives were older (median=49 years; IQR=40–58) than COVID-19 negatives (median=49 years; IQR=38–57) with p value of <0.05. Multivariable analysis showed that age at assessment (OR=1.02; 95% CI=1.00 to 1.03; p=0.016) and non-white ethnicity (black OR=4.30, 95% CI=2.92 to 6.31, p<0.001; South Asian OR=2.42, 95% CI=1.50 to 3.93, p<0.001) were associated with confirmed COVID-19. There was no significant interaction between ethnicity and vitamin D deficiency (OR=0.90; 95% CI=0.66 to 1.23; p=0.515). Median vitamin D concentration at recruitment was lower for people with subsequent confirmed COVID-19 (28.7 (IQR 10.0–43.8) nmol/L) than for other participants (32.7 (IQR 10.0–47.2) nmol/L) (p<0.01). Although univariable analysis suggested an association between vitamin D and COVID-19 (OR=0.99; 95% CI 0.99 to 0.999; p=0.013), this association became insignificant (OR=1.00; 95% CI=0.998 to 1.01; p=0.208) after adjustment for covariates.

Ilie et al. used an ecological study design reporting on 20 European countries as at 8 April 2020; the data pertain to mean levels of vitamin D, cases of COVID-19 per million population and deaths from COVID-19 per million population. The authors performed Pearson’s correlation coefficient calculations and reported a negative correlation between mean levels of vitamin D (mean 56.79 nmol/L, SD 10.61) and numbers of cases of COVID-19 per million population in each country (mean cases 1393.4, SD 1129.98, r(20) = −0.44; p=0.05). Additionally, a negative correlation was reported between mean vitamin D levels and the number of deaths caused by COVID-19 per million population in each country (mean 80.42, SD 94.61, r(20) = −0.4378; p=0.05). Sweden had the highest mean level of vitamin D (73.5 nmol/L) compared with Spain which had a mean level of 42.5 nmol/L. The number of cases of COVID-19 per million population was 834 in Sweden and 3137 in Spain. Likewise, at the time of the study, there were 68 deaths from COVID-19 in Sweden compared with 1937 in Spain.
| Study          | Design/setting                  | Population                                                                 | Exposure/intervention                                                                 | Outcomes                        | Results                                                                                                                                                                                                                                                                                                                                 | Limitations                                                                                                                                                                                                                                                                                                                                 |
|---------------|---------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D’Avolio et al | Cross-sectional study           | Canton of Tessin, Switzerland                                               | Vitamin D analysis, conducted within 7 weeks of the SARS-CoV-2 PCR result. Control patients with 25(OH)D data during the same period. | SARS-CoV-2 infection            | Group 1 comprised 27 patients with positive PCR test results for SARS-CoV-2, while group 2 comprised 80 patients with a negative PCR result for SARS-CoV-2. Significantly lower 25(OH)D levels (p=0.004) in SARS-CoV-2 patients even after stratifying patients according to age >70 years. Few patients from a single hospital. No available clinical information about the severity of COVID-19 symptoms. No data on other potential confounding variable SARS-CoV-2 and the 25(OH)D status were performed on different days. |
| Hastie et al  | Retrospective cohort study       | UK Biobank, cohort including England, Scotland and Wales                   | Biochemical assay of 25(OH)D, a measure of vitamin D status. Vitamin D was imputed if it was below or above the limit of detection. | Confirmed COVID-19 (at least one positive test result) | Complete data on 34,8598 UK Biobank participants 449 had confirmed COVID-19. Of these, 385 (85.8%) were white compared with 64 (14.2%) non-white (black, South Asian and others). Vitamin D was associated with COVID-19 univariably but not after adjustment for confounders. Ethnicity was associated with COVID-19. UK Biobank is not representative of the general population. Baseline measurements, including 25(OH)D concentration and health status, were obtained a decade prior to conduct of the study. |
| Ilie et al    | Ecological study                 | 20 European countries                                                      | Mean levels of vitamin D in each country                                             | Cases of COVID-19 per 1 million population in each country. Deaths from COVID-19 per 1 million population. | Negative correlations between mean levels of vitamin D and the number of COVID-19 cases per 1 million, and mortality per 1 million. The number of cases per country is affected by the number of tests performed and by the different measures taken by each country to prevent the spread of infection. |
| Fasano et al  | Case-control survey              | 1486 Parkinson’s disease (PD) patients were included in the survey 1207 family members (controls) | Vitamin D ‘Confirmed’ or ‘probable’ diagnosis of COVID-19                             | 12.4% of PD patients with confirmed or probable COVID-19 had been taking vitamin D. 22.9% of PD patients without COVID-19 had been taking vitamin D.                                                                 | Well-known limitation of a telephone survey. Community-dwelling PD patients. Some patients could not be reached possibly due to death from COVID-19. COVID-19 diagnosis could not be confirmed in many cases. Younger age of non-PD COVID-19 cases. |
COVID-19 per million population in Sweden and 314 in Spain.

**Vitamin D supplementation**

Fasano et al.44 investigated patients in a case–control phone survey in Lombardy, Italy. COVID-19 diagnosis was confirmed using a nasopharyngeal swab or probable based on (1) the presence of persistent COVID-19-related symptoms (≥3 including fever or ≥5 without fever); or (2) ≥1 symptom in the presence of suggestive chest radiologic signs; and/or (3) living with a family member with a confirmed diagnosis of COVID-19. A total of 1486 participants were included in the survey (32 confirmed COVID-19, 73 probable COVID-19 and 1381 unaffected). Confirmed/probable COVID-19 cases (mean age=70.5 (SD=10.1); male=53%) self-reported a significantly lower intake of vitamin D supplementation (12.4%) compared with unaffected cases (22.9%; mean age=73.0 (SD=9.5), male=57%). The age-adjusted OR (OR 0.56 (95% CI 0.32 to 0.99), p=0.048) suggested a protective effect of vitamin D intake.

**Subgroup evaluation**

We planned to perform subgroup analyses by age and ethnicity. According to Hastie et al.20 multivariable analysis showed that age at assessment (OR=1.02; 95% CI=1.00 to 1.03; p=0.016) and non-white ethnicity (black OR=4.30, 95% CI=2.92 to 6.31, p<0.001; South Asians OR=2.42, 95% CI=1.50 to 3.93, p<0.001) were associated with confirmed COVID-19. However, Hastie et al found no significant interaction between ethnicity and vitamin D deficiency (OR=0.90; 95% CI=0.66 to 1.23; p=0.515).

**DISCUSSION**

This systematic review of non-randomised studies has shown no robust evidence of an association between vitamin D and COVID-19. We identified four studies for inclusion in a narrative synthesis which were all at high or unclear risk of bias. A univariable analysis of data from the UK Biobank database revealed an association between vitamin D and COVID-19 (OR=0.99; 95% CI 0.99 to 0.999; p=0.013). However, this association became insignificant (OR=1.00; 95% CI=0.998 to 1.01; p=0.208) after adjustment for 13 other covariates, suggesting that the initial association was due to one or more confounding variables.70 This view is further strengthened by the demonstration of highly significant associations between age and ethnicity characteristics as predictor variables and COVID-19 as the outcome variable. Overall, the UK Biobank study showed no effect; however, it should be noted that the UK Biobank data included only one measurement of vitamin D levels taken between 10 and 14 years prior to the outbreak of COVID-19. This is a significant study limitation.

Liu et al.75 concluded that patients over 60 years experienced more severe manifestations and had longer disease courses of COVID-19 compared with patients below 60 years.75 And other studies have shown that older (rather than younger) people are more likely to die from COVID-19.76–79

Non-white people are known to be more susceptible to COVID-19 and tend to develop worse outcomes,80 a finding that our review has further substantiated.70 Ethnicity is a multifaceted construct that includes genetic makeup, sociocultural identity and behavioural patterns.81 It has been shown to be associated with differing susceptibility and treatment outcomes in a number of diseases.82–84 Hastie et al.20 did not find any interaction between ethnicity and vitamin D deficiency and although Ilie et al.71 identified a relationship, the study is subject to ecological bias. Ilie et al.83 compared vitamin D levels and rates of COVID-19 across 20 European countries, and therefore many relevant factors were not accounted for in the analysis. Given the findings so far from our review, we consider that there is paucity of data on vitamin D levels and morbidity and mortality from COVID-19 and there is no evidence from RCTs on outcomes of vitamin D supplementation on severity of symptoms or mortality to date. However, a relationship between ethnicity, vitamin D (serum levels or supplementation) and susceptibility to or severity of COVID-19 cannot yet be ruled out.

Risk of bias assessments demonstrate that all studies were at high or unclear risk of bias. All studies were observational designs and therefore, subject to confounding. The persistent calls for high-dose vitamin D supplementation arise from speculation about presumed mechanisms.86,87 Our systematic review found no robust evidence that low levels of vitamin D are associated with an increased likelihood of COVID-19. More robust prognostic studies could be combined in a systematic review where a prognostic factor research question is phrased, and considerations of participation, attrition, prognostic factor measurement, confounding measurement and account, outcome measurement, and analysis and reporting are evaluated.

Our systematic review identified no relevant RCTs; nevertheless, we are aware of two ongoing RCTs investigating the effects of vitamin D on COVID-19, the ZnD3-CoVici study, France (NCT04351490)88 and the CoVitTrial, France (NCT04344041).89 Both trials have an estimated study completion date of July 2020. Inclusion of data from these studies in future systematic reviews and meta-analyses may enable us to potentially draw better stronger conclusions on this topic. Results from the ongoing international VITDALIZE study (NCT03188796) may also contribute to our understanding of the effect of high-dose vitamin D₃ on mortality.90

**Study limitations**

We performed a full systematic review of the published evidence available, and simultaneous independent screening, data extraction and risk of bias assessments. However, our study is limited by the small amount of evidence available which was, moreover, at risk of bias. This limits the inferences that can be drawn. Seven
elgible studies were excluded because they are not available as peer-reviewed publications.63–69 If published, these seven studies would be included in a future update of this review. A final limitation is that the review was restricted to English language only. Therefore, articles published in other languages may have been excluded.

Implications for practice
Our review does not provide evidence for or against additional or high-dose vitamin D supplementation specifically in relation to COVID-19. Treatment as standard practice for people who are deficient is pre-existing practice across Europe23, the USA22 and in the UK.21 Current guidelines from PHE suggest that the entire UK population should take vitamin D supplements to prevent vitamin D deficiency in winter or with inadequate sunlight exposure to sun in summer.21 This review does not give evidence to drive a change in this current advice. Treatment recommendations for patients should be updated following the publication of results from ongoing and new well-designed adequately powered randomised controlled trials.

CONCLUSION
This systematic review identified no robust evidence to enable us to assess an association between vitamin D supplementation or serum vitamin D level with susceptibility to COVID-19 including clinical course, morbidity and mortality outcomes. All studies were at high or unclear risk of bias. Both age and ethnicity were associated with vitamin D levels even after multivariable adjustment. Black and South Asian people had a much higher risk of confirmed COVID-19 compared with white people. However, there was no interaction between the association of ethnicity and vitamin D deficiency with COVID-19. There were no papers reporting association of vitamin D with severity of symptoms or mortality due to COVID-19.

Author affiliations
1Division of Health Sciences, Warwick Medical School, The University of Warwick, Coventry, UK
2Department of Pharmaceutical Nanotechnology, University of Medical Sciences, Mashhad, Iran (the Islamic Republic of)
3Warwick-Centre for Applied Health Research (WCAHRD), University of Warwick, Coventry, UK
4Warwick Medical School, The University of Warwick, Coventry, UK

Acknowledgements We thank Kath Charters, Welsh Ambulance Services NHS Trust, for comments on the study design and drafts of this manuscript and for valuable advice and helpful discussions.

Contributors SK, AG and AC conceived the study. AG, AC, NM, SK, ST-P and OAU designed the study. RC and AB developed the search strategies, performed all searches and database management, and created the bibliography. AG, AC, AM, OO, MZ screened titles and abstracts for inclusion. AG, OO, AM, MZ, LA-K and AC screened at full text and extracted and analysed data. OO, AM, MZ and LA-K performed risk of bias assessments. AC, SK and NM assisted in the interpretation from a clinical perspective. ST-P, LA-K and OU offered technical and methodological support. AG, OO and MZ wrote the first draft, all authors revised content. All authors approved the final manuscript. AG and AC are the guarantors. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding Dr AG is supported by the National Institute for Health Research (NIHR) Advanced Fellowship Programme Reference (AF-300060). Dr ST-P is supported by an NIHR Career Development Fellowship (CDF-2016-09-018). Professor AC and Dr LA-K are supported by the NIHR Applied Research Centre West Midlands (ARC-WM). All other authors, with the exception of Professor Uthman, Professor SK and Professor NMC, are supported by the NIHR, Evidence Synthesis Programme (HTA 14.25.05). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. The study protocol is available systematic review protocol registration: CRD42020182876 available online via PROSPERO at https://www.crd.york.ac.uk/ prospero/display_record.php?ID=CRD42020182876. All included studies are publicly available. Additional data are available on reasonable request by emailing the corresponding author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Amy Grove http://orcid.org/0000-0002-8027-7274
Amin Mehrabian http://orcid.org/0000-0002-8879-7565
Sian Taylor-Phillips http://orcid.org/0000-0002-1841-4346
Olealekan A Uthman http://orcid.org/0000-0002-8567-3081

REFERENCES
1 World Health Organization. Coronavirus disease (COVID-19) pandemic. 2020. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2 NHS. Check if you or your child has coronavirus symptoms. 2020. Available: https://www.nhs.uk/conditions/coronavirus-covid-19/symptoms/
3 Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 2020;369:m1996.
4 Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respir Med 2020;8:433–4.
5 Gruber BM, Fenomen vitamin D [The phenomenon of vitamin D]. Postepy Hig Med Dosw 2015;69:127–39.
6 Gruber–Bzura BM. Vitamin D and influenza: prevention or therapy? Int J Mol Sci 2018;19:2419.
7 Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81:353–72.
8 Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007;8:285–93.
9 Kogawa M, Findlay DM, Anderson PH, et al. Osteoclastic metabolism of 25(OH) vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology 2010;151:4613–25.
10 Jones G. Vitamin D safety: its mechanisms and application. Standardy Medyczne, Pediatria 2012;9:605–9.
11 Kim D. The role of vitamin D in thyroid diseases. Int J Mol Sci 2017;18:1949.
12 Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol 2011;50:194–200.
Lee J, van Hecke O, Roberts N, on behalf of the Oxford COVID-19 Evidence Service Team. Vitamin D: a rapid review of the evidence for treatment or prevention in COVID-19. Centre for evidence-based medicine, University of Oxford, 2020. https://www.cebm.net/covid-19/vitamin-d-a-rapid-review-of-the-evidence-for-treatment-or-prevention-in-covid-19/

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.

World Health Organization. Global report on chronic non-communicable diseases and health systems: a WHO evidence report. Geneva, 2017. Available: https://apps.who.int/iris/bitstream/handbook/book-9789241510031-en/WHO_devices.pdf

Cannell JJ, Vieth R, Umhau JC, Holick MF, Chait A, Safford M, et al. 2004;134:1129–40. Epidemic influenza and vitamin D supplementation to prevent acute respiratory tract infections: a randomized placebo-controlled trial. APMIS 2017;125:681–97.

Cantonra MT, Snyder L, Lin Y-D, et al. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients 2015;7:3011–21.

Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell proliferation and promote development of regulatory T cells expressing CTLA-4 and FOXP3. J Immunol 2009;183:5458–67.

Lei G-S, Zhang C, Cheng B-H, et al. Mechanisms of action of vitamin D as supplemental therapy for Pneumocystis pneumonia. Antimicrob Agents Chemother 2017;61:e01226–17.

Colunga Biancatelli RML, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti Infect Ther 2020;18:99–101.

Scientific Advisory Committee on Nutrition. SACN vitamin D and COVID-19: do deficient risk a poor outcome? Ref: 2020;51:995–6.

Royal Society. Vitamin D and covid-19. Available: https://royalsociety.org/-/media/policy/projects/set-c-set-c-vitamin-d-and-covid-19.pdf [Accessed 18 Jun 2020].
69 Tan CW, LP H, Kalimuddin S. A cohort study to evaluate the effect of combination vitamin D magnesium and vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients. medRxiv 2020.

70 Hastie CE, Mackay DF, Ho F, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr 2020;14:561–5.

71 Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 2020;32:1195–8.

72 UK Biobank. About UK Biobank. Available: https://www.ukbiobank.ac.uk/about-biobank-uk/ [Accessed 17 Jun 2020].

73 D’Avolio A, Avataneo V, Manca A, et al. 25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients 2020;12:1359.

74 Fulzele S, Sahay B, Yusufu I, et al. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profie. Aging Dis 2020;11:509–22.

75 Verity R, Okell LC, Dorigati I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20:669–77.

76 Lee C. “Race” and “ethnicity” in biomedical research: how do scientists construct and explain differences in health? Soc Sci Med 2009;68:1183–90.

82 Stead WW, Senner JW, Reddick WT, et al. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990;322:422–7.

83 Nahid P, Horne DJ, Larsby LG, et al. Racial differences in tuberculosis infection in United States communities: the coronary artery risk development in young adults study. Clin Infect Dis 2011;53:291–4.

84 Verity R, Okell LC, Dorigati I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20:669–77.

85 Lanham-New SA, Webb AR, Cashman KD. Vitamin D and SARS-CoV-2 virus/COVID-19 disease. BMJ Nutrition, Prevention & Health 2020;bmjphp-2020-000089.

86 Huang F, Zhang C, Liu Q, et al. Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury. PLoS Pathog 2020;16:e1008341.

87 Lee C. Controversial effects of vitamin D and related genes on viral infections, pathogenesis, and treatment outcomes. Nutrients 2020;12:962.

88 U.S National Library of Medicine. Impact of zinc and vitamin D3 supplementation on the survival of aged patients infected with COVID-19. NCT04351490, 2020. Available: https://clinicaltrials.gov/show/NCT04351490

89 U.S National Library of Medicine. COvid-19 and Vitamin D supplementation: a multicenter randomized controlled trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients (CoVitTrial). NCT04344041, 2020. Available: https://clinicaltrials.gov/show/NCT04344041

90 U.S National Library of Medicine. The VITDALIZE Study: effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients. NCT03188796, 2017. Available: https://ClinicalTrials.gov/show/NCT03188796